Litcius/Paper detail

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prébet, Sang‐Min Lee, Gary J. Schiller, Shira Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen Seiter, Andrew H. Wei, Stéphane de Botton, Montserrat Arnán, Will Donnellan, Anthony P. Schwarer, Christian Récher, Brian A. Jonas, P. Brent Ferrell, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jörge E. Cortes

2022The Lancet Haematology117 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAzacitidineMyelodysplastic syndromesInternal medicinePharmacodynamicsPharmacokineticsMyeloidPhases of clinical researchIDH1Clinical trialGastroenterologyOncologyBone marrowGene expressionMutationChemistryBiochemistryGeneDNA methylationAcute Myeloid Leukemia ResearchBiochemical and Molecular ResearchBlood disorders and treatments
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial | Litcius